 Shares of Prevail Therapeutics Inc. nearly rocketed 98.3 in premarket trading Tuesday, after the gene therapy company agreed to be acquired by Eli Lilly Co. in a deal with a total value of 1.04 billion. Lillys stock edged up 0.5 ahead of the open. 